Patients with driver mutation absent advanced NSCLC are stratified according to their programmed death-ligand 1 (PD-L1) levels for the initial choice of treatment; if the PD-L1 level is higher than 50% treatment is started with pembrolizumab, if lower than 50%, a chemotherapy immunotherapy combination is preferred. Here, CD274 is linked to non-small cell lung carcinoma.